GCCL participated as a platinum sponsor at Asia Bio Partnering Forum 2026 in Singapore from August 31 to September 2, pursuing partnerships with global contract research organizations (CROs), Singapore-based institutions and drug developers across the Asia-Pacific region. The event attracted about 650 participants and hosted roughly 2,500 partnering meetings. GCCL discussed existing and expanded cooperation with global CROs, met Singapore-based pharmaceutical, diagnostics and clinical trial service companies, and explored collaboration with a Singapore government economic development agency to support local drug developers. At its booth, the company presented bioanalysis services spanning the clinical trial cycle and analytical method development capabilities. Discussions covered demand linked to mRNA, nucleic acid therapeutics and radiopharmaceuticals in South Korea, China, Japan, Singapore, Vietnam and Europe. GCCL said it holds certification across all Good Clinical Laboratory Practice (GCLP) areas for clinical trial bioanalysis from South Korea's Ministry of Food and Drug Safety and provides bioanalysis, analytical method development and consulting services to pharmaceutical and biotechnology companies.